Drugs / apamistamab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07157514 | Jan 2026 → Feb 2029 expected | acute myeloid leukemia, disease related to transplantation | Actinium Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | apamistamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157514 ↗ |
| Modality | Monoclonal antibody | “Iodine-131 radiolabeled anti-CD45 monoclonal antibody” NCT07157514 ↗ |
| Route | Intravenous | “Administered IV as a dosimetric dose followed by treatment dose.” NCT07157514 ↗ |